

Remarks

SEQ ID NO. 3 has been amended. In the substitute Sequence Listing filed May 28, 2002, the C-terminal amino acid glycine (at SEQ ID NO. 3, position 31) was inadvertently left out. The corrected SEQ ID NO. 3 is submitted herewith.

Applicant's attorney hereby states that the change made in the sequence listing does not include new matter. Support for this amendment can be found, inter alia, in Figure 1. Applicant's undersigned attorney has amended the specification only to direct the entry of this corrected Sequence Listing at the end of the application.

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

Summary

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Michele A. Cimbala
Attorney for Applicant
Registration No. 33,851

Date: March 5, 2003
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600
::ODMA\MHODMA\SKGF_DC1;107464;1
SKGF Rev. 1 1/26/01 mac